Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal
Stromal Tumors (GIST)

GIST is a rare cancer affecting the gastrointestinal (GI) system. In most cases, GISTs arise in the stomach or small intestine, but can form anywhere along the digestive tract. GISTs are most often driven by genetic mutations in the KIT tyrosine kinase receptor gene.

GIST can advance and spread to other parts of the body including the lungs and bone. Progression of GIST varies widely depending on the location, size, and aggressiveness of the tumor. In addition to surgery, GIST is often treated with KIT/ PDGFR⍺ tyrosine kinase inhibitors such as imatinib in the first line and sunitinib in the second line.

You’re not alone on your GIST journey.

GISTPathways.com is an online resource offering support, education, and information for those living with GIST and their caregivers.

Our GIST Clinical Trial

FULLY ENROLLED

Peak is a Phase 3 clinical trial evaluating bezuclastinib (CGT9486), a selective and potent KIT inhibitor, in combination with sunitinib vs. sunitinib alone, in people with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors (GIST) who have previously received imatinib.

GIST HOPE Mosaic

We were honored to partner with The Life Raft Group and GIST community to build this wonderful photo mosaic honoring those who have been impacted by GIST. The stories and images are truly inspiring. It’s incredible to see the impact we can have when we come together as a community to help build hope together!

Community Updates & Resources

Community Updates:

Letter to the GIST Community – September 2024
Current updates from Cogent for the GIST Community

Resources:

An Introduction to GIST
A resource for those newly diagnosed that provides general information about GIST including: diagnosis, treatment and management, questions to ask your provider and more.

Subscribe for Email Updates

Sign-up to receive email updates from Cogent about Gastrointestinal Stromal Tumors related news, including information about clinical trials and programs that Cogent offers or sponsors.

First Name*

Last Name*

Email*

Zip Code*

Other Diagnosis

I am interested in:

GIST

Systemic Mastocytosis

Indolent Systemic Mastocytosis

Smoldering Systemic Mastocytosis

Advanced Systemic Mastocytosis

Aggressive Systemic Mastocytosis

Mast Cell Leukemia (MCL)

Systemic Mastocytosis with an Associated Hematologic Neoplasm (SM-AHN)

I am Interested Other

Marketing by

Cole is an accomplished executive with extensive commercial development, new product launch, P&L, and strategic leadership experience over a 20 plus year career in the pharmaceutical industry, with a specific focus on oncology. Before joining Cogent as Chief Commercial Officer, he served at Pfizer as the Global Franchise Lead for its Genitourinary, Lung and Breast Oncology Businesses. In this role, he oversaw the global launch and lifecycle strategy for Xtandi® + Talzenna® in mCRPC. Before that, he was President of Pfizer Canada where he was accountable for the company’s operations within the country, including sales, marketing, access and government relations. He was also VP of a US commercial business unit which had tremendous growth under his leadership. Prior to working at Pfizer, Cole held management positions at both Hospira, Inc., a global pharmaceutical and medical device company, in global pharmaceuticals, global marketing and commercial development. He holds an MBA from the University of Chicago Booth School of Business, a Master of Science degree in Microbiology from Iowa State University, and a Bachelor’s Degree in Biology from St. Olaf College. In his spare time, Cole enjoys swimming, hiking and skiing.